Major changes in the sphingophospholipidome of HDL in non-diabetic patients with metabolic syndrome

Atherosclerosis
Damien DenimalLaurence Duvillard

Abstract

Phospholipids and sphingolipids play a critical role in the protective effects of HDL against atherosclerosis. These properties are impaired in patients with metabolic syndrome, before the development of diabetes. We thus investigated whether HDL from patients with metabolic syndrome but normal fasting glycaemia present abnormalities in their sphingophospholipid profile. Using liquid chromatography/tandem mass spectrometry, we quantified the different species of the main phospholipids and sphingolipids in the HDL2 and HDL3 from 26 obese patients with metabolic syndrome but normal fasting glycaemia and 50 controls. Phosphatidylcholines, when expressed as the relative amount compared with total phospholipids and sphingolipids, were similar in both HDL2 and HDL3 in the two groups. Lysophosphatidylcholines were 41% (p = 0.0002) and 86% (p < 0.0001) higher in HDL2 and HDL3, respectively, from patients with metabolic syndrome than in those from controls. Phosphatidylinositols were also higher in HDL2 and HDL3 (respectively, +60 and + 103% (p < 0.0001)). In contrast, both HDL2 and HDL3 from patients with metabolic syndrome showed lower proportions of phosphatidylethanolamine-based plasmalogens (respectively -78 and -73%, p < 0.0001), ...Continue Reading

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Aug 21, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·F PontB Vergès
Sep 17, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·C F EbenbichlerJ R Patsch
Mar 5, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·John F KeaneyUNKNOWN Framingham Study
Feb 18, 2004·The Journal of Clinical Investigation·Jerzy-Roch NoferBodo Levkau
Dec 16, 2004·The Journal of Clinical Investigation·Shigetada FurukawaIichiro Shimomura
Jun 23, 2006·Journal of Lipid Research·Yun WangDonald B Jump
Jul 9, 2008·The Journal of Biological Chemistry·Kelley M ArgravesW Scott Argraves
Nov 14, 2008·The New England Journal of Medicine·T PischonE Riboli
Feb 10, 2009·Lipids·Faidon MagkosBettina Mittendorfer
Apr 14, 2009·The Journal of Clinical Investigation·Hélène L KammounFabienne Foufelle
Jan 18, 2011·Free Radical Biology & Medicine·Agnieszka BroniecTadeusz Sarna
Apr 2, 2013·Journal of Lipid Research·Anatol KontushM John Chapman
Sep 17, 2013·PloS One·Greg M KowalskiClinton R Bruce
Jul 1, 2014·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Katherine SattlerBodo Levkau
Jun 18, 2015·European Journal of Clinical Investigation·Eke G GruppenRobin P F Dullaart
Jul 21, 2015·Biochimica Et Biophysica Acta·Peng Yang, Papasani V Subbaiah

❮ Previous
Next ❯

Citations

Jun 7, 2017·Journal of Alzheimer's Disease : JAD·Kevin HuynhPeter J Meikle
Jan 24, 2018·Disease Models & Mechanisms·Gema Marín-RoyoVictoria Cachofeiro
Dec 13, 2019·JCI Insight·Mathias CardnerArnold von Eckardstein
Jul 1, 2021·The Journal of Nutritional Biochemistry·Marcos Yukio YoshinagaMarcelo Macedo Rogero

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.